Drug Tariffs May Put Smaller Manufacturers Under Greater Pressure
Goldlaner.com – A new 100% tariff on selected patented medicines and pharmaceutical ingredients is set to begin Tuesday, placing the Trump administration’s effort to encourage more US drug production under close scrutiny. While the policy is intended to shift manufacturing activity into the country, its strongest effects may be felt by smaller drug companies with limited ability to quickly move their supply chains.
Many of those companies rely on outside manufacturers rather than operating their own production sites. Finding US-based capacity can be costly and difficult, particularly when contract manufacturers are already competing for available space. The result could be higher operating costs, fewer independent companies and, potentially, more expensive medicines for patients.
Who Is Covered by the New Tariffs
The tariff program does not apply evenly across the pharmaceutical sector. Large manufacturers that entered into “Most Favored Nation” agreements are excluded from the highest levy. In those arrangements, companies committed to increase domestic manufacturing and to offer lower prices through Medicaid and TrumpRx, the administration’s direct-to-consumer clearinghouse.
Those larger firms produce most branded drugs. Other important categories are also largely outside the scope of the new tariff: generic medicines, orphan drugs used for rare conditions and certain specialty treatments.
Trade arrangements further narrow the number of products facing the 100% rate. Patented pharmaceutical goods arriving from the European Union, Switzerland, Japan and South Korea will receive a 15% tariff rate under existing bilateral trade deals. Products from the United Kingdom will not be subject to the levies, while companies that have agreements to expand US production will face a 20% rate.
Because of these exemptions and lower rates, only a relatively small slice of drugmakers and products will be hit by the full tariff. Still, that group includes more than 100 manufacturers with at least one non-exempt medicine, based on a preliminary Brookings Institution review.
A Difficult Shift for Smaller Companies
The central challenge is that many affected companies may not have facilities they can simply expand. A majority use contract manufacturers to produce their medicines, leaving them dependent on a market where US capacity is in especially high demand.
Marta Wosinska, a senior fellow at Brookings, has described the competition for domestic contract manufacturing capacity as unusually intense. For smaller companies, building facilities or securing new production agreements could require resources that are beyond reach.
“Their pockets are not as deep,” Wosinska said of the smaller companies.
If businesses cannot obtain relief through negotiations with the White House or find affordable domestic production options, some may be pushed toward sales or mergers with larger pharmaceutical rivals. Consolidation could change the range of medicines available, especially when a smaller company serves a narrow patient population that is not a major priority for the industry’s largest players.
Potential Consequences for Patients
Patients could face the greatest disruption when they depend on treatments made by smaller manufacturers. Tariffs increase the cost of imported products and ingredients, and companies may try to recover some of that expense through higher prices.
Mollie Sitkowski, an international trade lawyer with Faegre Drinker, expects prices for such medicines to rise. She also anticipates that the number of new drugs entering the market could decline over the coming years.
That concern extends beyond today’s prescriptions. Smaller biotechnology and pharmaceutical businesses often focus on specialized treatments and early-stage research. If more capital is directed toward tariffs, supply-chain changes and domestic manufacturing negotiations, less may remain for clinical development and research programs.
Innovation Concerns Emerge
The Biotechnology Innovation Organization, which represents small and midsize drugmakers, warned the Commerce Department earlier this month that the policy could weaken the investment needed to sustain innovation.
“Tariffs that punish U.S. innovators are counterproductive and risk slowing the investment and innovation needed to be successful.”
John Crowley, BIO’s chief executive officer, argued that higher import costs could work against the broader goal of strengthening the nation’s biotechnology sector.
“The reality is that tariffs on America’s medicines will raise costs, impede domestic manufacturing, and divert scarce resources away from research and development critical to maintaining American biotech leadership,” Crowley wrote.
The administration announced the pharmaceutical tariffs in April, following earlier signals from President Donald Trump that the industry would become a target. Drug products had avoided broad tariff treatment for decades in part because of an international framework intended to keep essential medicines moving across national borders.
The new policy marks a notable departure from that approach, even with its lengthy list of exceptions. Its practical success will depend on whether affected companies can secure US manufacturing arrangements without sacrificing the investment required to develop and supply medicines. For patients, the key questions will be whether their treatments remain available and whether prices stay within reach.
Related Reading
Frequently Asked Questions
What is Trump s huge tariffs on some?
Trump s huge tariffs on some is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.
Why does Trump s huge tariffs on some matter?
Trump s huge tariffs on some matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.